UnknownNot Applicable

Evaluation of the DALY on a Cohort of Patients With Indolent Systemic Mastocytosis

France160 participantsStarted 2023-05-01

Plain-language summary

Mastocytosis is a group of pathologies characterized by the accumulation and/or clonal proliferation of abnormal mast cells in various organs. The impact of mastocytosis on health, quality of life, the psychoaffective sphere and on professional life constitutes the burden of this disease. The DALY is the disability-adjusted life expectancy, which takes into account the life expectancy and the number of years "lost" due to illness, disability or early death. Due to the major impact of the disease this study evaluates the DALY in indolent mastocytosis patients

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Having expressed their non opposition to participate in this study * Diagnosed with indolent mastocytosis and cared for in the CEREMAST reference center in Toulouse Exclusion Criteria: * Patient with a form of mastocytosis other than MSI * Patient under legal protection, guardianship or curatorship

What they're measuring

DALY

Timeframe: Day 1

Trial details

NCT IDNCT05923372

SponsorUniversity Hospital, Toulouse

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-05-01

Contact for this trial

Cristina BULAI LIVIDEANU, MD

0567778138 livideanu.c@chu-toulouse.fr

View on ClinicalTrials.gov More Mastocytosis, Indolent Systemic trials